Skip to main content
AAPL+0.64%MSFT+1.07%NVDA+0.64%GOOGL+0.80%AMZN+1.46%SPCX+1.27%TSM+0.81%AVGO+3.64%META+0.81%TSLA+0.74%LLY-2.33%WMT-0.13%AMD+5.31%SKHY-0.11%JPM-1.77%BRK-B-2.07%MU+1.55%V-0.37%JNJ-2.15%XOM-3.97%MA-0.37%ASMLa+1.94%ABBV-2.33%COST-1.21%1398.HK-0.22%0700.HK-6.09%KO-0.71%CVX-4.74%PG-0.83%CSCO+2.18%0939.HK-0.14%ORCL-0.97%3988.HK-0.04%GE+0.52%BAC-1.07%HD-0.40%1816.HK-26.27%0857.HK-1.46%UNH-10.21%1288.HK-1.27%PM-0.85%0005.HK-1.87%NVS-2.46%HSBA.L-2.00%INTC-0.91%MS-1.29%AMAT+0.88%AP2d+2.23%AZN-1.93%TXN-1.16%AUDJPY-1.66%AUDUSD-1.51%EURAUD+1.03%AUDCHF-1.00%AUDNZD-0.98%AUDCAD-0.97%GBPAUD+0.96%GBPJPY-0.71%NZDJPY-0.71%CADJPY-0.70%EURJPY-0.67%CHFJPY-0.66%AUDSGD-0.63%AUDDKK-0.58%USDCAD+0.55%USDCHF+0.53%GBPUSD-0.53%NZDUSD-0.53%EURUSD-0.50%AUDNOK-0.47%GBPTRY+0.41%NZDMXN+0.39%USDMXN+0.32%GBPHKD+0.32%USDZAR+0.30%GBPMXN-0.28%USDTHB+0.25%EURZAR+0.24%GBPZAR+0.22%USDTRY+0.21%USDJPY-0.18%CHFNOK+0.17%USDILS+0.16%USDNOK+0.15%USDCNH-0.13%NOKJPY-0.11%CHFSEK+0.10%EURNOK+0.10%EURCNH-0.10%USDPLN+0.09%USDSEK+0.09%NZDSGD+0.09%GBPSGD-0.07%EURHKD-0.06%USDDKK+0.05%EURGBP+0.05%EURCAD+0.05%EURSGD-0.05%PLNJPY-0.05%SGDJPY+0.05%EURSEK+0.04%EURCZK+0.04%USDCOP-0.04%EURCHF+0.04%EURPLN+0.04%EURNZD+0.03%NZDCHF-0.03%CADCHF-0.02%CHFSGD+0.02%USDHKD-0.01%GBPCHF-0.01%USDSGD+0.01%GBPCAD-0.01%NZDCAD0.00%GBPNZD0.00%EURDKK0.00%W1-0.76%XNGUSD-0.61%C1-0.55%UKOIL+0.52%S1-0.39%USOIL+0.32%XAUUSD+0.24%GAUUSD+0.24%XPTUSD-0.22%XAGUSD+0.20%GAGUSD+0.20%COTTON+0.15%BTCUSD-3.51%ETHUSD+57.77%USDTUSD-0.02%XRPUSD+52.58%SOLUSD+57.55%TRXUSDT+0.77%ZECUSDT-6.76%XMRUSDT-1.71%DOGEUSD+55.95%LINKUSD-3.40%XLMUSD-3.79%BCHUSDT-3.59%LTCUSD+47.50%UNIUSD-3.05%SUIUSD-3.20%TONUSD+59.18%HBARUSDT-5.05%TAOUSDT-3.41%AAVEUSD-3.74%ONDOUSDT-5.51%ICPUSDT-2.22%DOTUSDT-3.90%WLDUSDT-3.57%ARBUSDT-5.68%ATOMUSDT-2.50%INJUSDT-7.97%STXUSDT-3.10%PYTHUSDT-0.76%TIAUSDT-3.37%FETUSDT-4.46%JUPUSDT+0.25%SEIUSDT-4.48%GRTUSDT-3.56%OPUSDT-3.90%IOTAUSDT-2.66%POLUSDT-2.10%WIFUSDT-2.98%AXSUSDT-2.91%EOSUSDT-4.24%IMXUSDT-3.36%FARTCOINUSDT-6.54%GALAUSDT-2.38%DYDXUSDT-2.63%ORDIUSDT-2.62%NOTUSDT+0.86%RONINUSDT-2.92%AAPL+0.64%MSFT+1.07%NVDA+0.64%GOOGL+0.80%AMZN+1.46%SPCX+1.27%TSM+0.81%AVGO+3.64%META+0.81%TSLA+0.74%LLY-2.33%WMT-0.13%AMD+5.31%SKHY-0.11%JPM-1.77%BRK-B-2.07%MU+1.55%V-0.37%JNJ-2.15%XOM-3.97%MA-0.37%ASMLa+1.94%ABBV-2.33%COST-1.21%1398.HK-0.22%0700.HK-6.09%KO-0.71%CVX-4.74%PG-0.83%CSCO+2.18%0939.HK-0.14%ORCL-0.97%3988.HK-0.04%GE+0.52%BAC-1.07%HD-0.40%1816.HK-26.27%0857.HK-1.46%UNH-10.21%1288.HK-1.27%PM-0.85%0005.HK-1.87%NVS-2.46%HSBA.L-2.00%INTC-0.91%MS-1.29%AMAT+0.88%AP2d+2.23%AZN-1.93%TXN-1.16%AUDJPY-1.66%AUDUSD-1.51%EURAUD+1.03%AUDCHF-1.00%AUDNZD-0.98%AUDCAD-0.97%GBPAUD+0.96%GBPJPY-0.71%NZDJPY-0.71%CADJPY-0.70%EURJPY-0.67%CHFJPY-0.66%AUDSGD-0.63%AUDDKK-0.58%USDCAD+0.55%USDCHF+0.53%GBPUSD-0.53%NZDUSD-0.53%EURUSD-0.50%AUDNOK-0.47%GBPTRY+0.41%NZDMXN+0.39%USDMXN+0.32%GBPHKD+0.32%USDZAR+0.30%GBPMXN-0.28%USDTHB+0.25%EURZAR+0.24%GBPZAR+0.22%USDTRY+0.21%USDJPY-0.18%CHFNOK+0.17%USDILS+0.16%USDNOK+0.15%USDCNH-0.13%NOKJPY-0.11%CHFSEK+0.10%EURNOK+0.10%EURCNH-0.10%USDPLN+0.09%USDSEK+0.09%NZDSGD+0.09%GBPSGD-0.07%EURHKD-0.06%USDDKK+0.05%EURGBP+0.05%EURCAD+0.05%EURSGD-0.05%PLNJPY-0.05%SGDJPY+0.05%EURSEK+0.04%EURCZK+0.04%USDCOP-0.04%EURCHF+0.04%EURPLN+0.04%EURNZD+0.03%NZDCHF-0.03%CADCHF-0.02%CHFSGD+0.02%USDHKD-0.01%GBPCHF-0.01%USDSGD+0.01%GBPCAD-0.01%NZDCAD0.00%GBPNZD0.00%EURDKK0.00%W1-0.76%XNGUSD-0.61%C1-0.55%UKOIL+0.52%S1-0.39%USOIL+0.32%XAUUSD+0.24%GAUUSD+0.24%XPTUSD-0.22%XAGUSD+0.20%GAGUSD+0.20%COTTON+0.15%BTCUSD-3.51%ETHUSD+57.77%USDTUSD-0.02%XRPUSD+52.58%SOLUSD+57.55%TRXUSDT+0.77%ZECUSDT-6.76%XMRUSDT-1.71%DOGEUSD+55.95%LINKUSD-3.40%XLMUSD-3.79%BCHUSDT-3.59%LTCUSD+47.50%UNIUSD-3.05%SUIUSD-3.20%TONUSD+59.18%HBARUSDT-5.05%TAOUSDT-3.41%AAVEUSD-3.74%ONDOUSDT-5.51%ICPUSDT-2.22%DOTUSDT-3.90%WLDUSDT-3.57%ARBUSDT-5.68%ATOMUSDT-2.50%INJUSDT-7.97%STXUSDT-3.10%PYTHUSDT-0.76%TIAUSDT-3.37%FETUSDT-4.46%JUPUSDT+0.25%SEIUSDT-4.48%GRTUSDT-3.56%OPUSDT-3.90%IOTAUSDT-2.66%POLUSDT-2.10%WIFUSDT-2.98%AXSUSDT-2.91%EOSUSDT-4.24%IMXUSDT-3.36%FARTCOINUSDT-6.54%GALAUSDT-2.38%DYDXUSDT-2.63%ORDIUSDT-2.62%NOTUSDT+0.86%RONINUSDT-2.92%
AT

Axsome Therapeutics, Inc. (AXSM)

NASDAQ • Healthcare

$134
-$1.94 (-1.4%)
Market closed

Last close at November 18, 2026 at 21:00 UTC

Open$135.65
Day Range$131.56 - $136.62
Avg. Volume (3M)1.1M
Market Cap$7B
52 Week Range
$123$260.19

Metrics Over Time

Where the Money Goes

Q3 2026
Revenueeverything earned$259.6M100%
Gross Profitminus cost of goods$241.8M93%

In plain terms: out of every $100 in revenue, Axsome Therapeutics, Inc. currently loses $5.

Fundamentals & Financials

Revenue (TTM)
$865.2M
Net Income (TTM)
-$157.2M
EPS (TTM)
-$3.06
ROA (TTM)
-19.02%
Current Ratio
1.42

TTM is calculated as the sum of the four most recently completed quarters. This is a standard approach when monthly or real-time data is not available.

Earnings

-48.2%Q2 2026-$1.26
-11.0%Q3 2026-$0.99
+60.6%Q4 2026-$0.25

% — EPS deviation from the forecast (beat / miss); quarters without a forecast show the reported EPS

Latest report — Q4 2026
Beat +60.6%

Axsome Therapeutics beat expectations on both the top and bottom line in the third fiscal quarter of 2026, reported November 2, 2026, with EPS of -$0.25 topping the -$0.63 estimate by $0.38 and revenue of $259.7 million topping the $249.2 million consensus (+4.2%). Revenue rose ~52% from about $171.0 million a year ago, led by Product Sales, which increased ~47% to roughly $250.0 million, while Royalty and Milestone Revenue climbed ~706% to about $9.7 million off a smaller base. Profitability stayed high at the gross line, with gross profit of roughly $241.9 million translating to a gross margin of ~93%, while operating results remained negative, with an operating margin of roughly -4% and operating income of about -$11.1 million. Net income was about -$12.9 million, improving ~73% from roughly -$47.2 million a year ago, and the EPS loss narrowed ~73% from -$0.94. Cash flow from operations was negative at about -$9.5 million. For the next period, consensus calls for EPS of -$0.06 on revenue of $286.8 million.

View full earnings history

About Axsome Therapeutics, Inc.

Axsome Therapeutics, Inc. is a Biotechnology company listed on the NASDAQ under AXSM that develops and commercializes central nervous system therapies in the United States. The company generated $638.5 million in revenue in FY2025 and focuses on prescription medicines and late-stage development candidates for neurologic and psychiatric conditions.

Name
Axsome Therapeutics, Inc.
CEO
Herriot Tabuteau
Industry
Healthcare
Year Founded
2012
Employees
1,346

Today's Snapshot

AI-generated

The day ended with AXSM 1.4% lower at 134.00, in line with a weaker sector. Volume was about two-thirds of its usual level.

Trading Volume

Below 10d avg (941.5K)

650.5K

vs S&P 500 Today

Underperforming Market

-1.17%

Updated: November 18, 2026 at 21:13 UTC

Technical Indicators

0 Buy3 Neutral5 Sell
AXSM exhibits a clear bearish profile: the ADX near 34 signals a strong downward trend while momentum measures and MACD are negative, reflecting selling pressure and weak short-term momentum. The stock is trading well below most moving averages, notably under the 200-day level, and sits near the lower half of its Bollinger band range, indicating limited near-term upside. Volatility is elevated with an ATR around 7.14, and on-balance volume is strongly negative, suggesting distribution. Price also sits just under the pivot level, reinforcing resistance overhead. Technical takeaway: Strong Sell — trend strength, negative momentum and weak volume favor the downside.
All signals
  • EMA (5 indicators)$138.80 - $182.46
    Sell
  • RSI (14)35.23
    Neutral
  • Stochastic %K (14, 3, 3)44.70
    Neutral
  • MACD Level (12, 26)-7.86
    Neutral
Stay Ahead of the Market

Get premium market insights delivered directly to your inbox.